Home Trials Current Trials CHARM: Cirara in large Hemispheric infarction Analysing mRS and Mortality

CHARM: Cirara in large Hemispheric infarction Analysing mRS and Mortality

E-mail Print PDF
Lead PI: Dr Bruce Campbell

Status: ASTN endorsed

No. of Patients Currently Recruited: 0                                No. of Patients Required: tbc

Edema in larger hemispheric infarction can cause neurological deterioration and death. Intravenous glyburide acts on SUR-1 receptors to reduce edema after ischemic stroke. The hypothesis of the CHARM phase 3 randomised trial is that intravenous glyburide will improve the functional outcome after large hemispheric stroke compared to placebo.
Last Updated ( Thursday, 07 July 2016 14:07 )  

Registered Charity



Latest news

Top Views